TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24670078

Group type: EXPERIMENTAL
Intervention: Forward-inclined seatpan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Backrest
Number of subjects: 12
Study: 22151772

Group type: EXPERIMENTAL
Intervention: Visual feedback cues
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Auditory feedback cues
Number of subjects: 10
Study: 20876405

Group type: EXPERIMENTAL
Intervention: Pine bark extract (200 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 17572643

Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen (665 mg modified-release tablets, three times a day for five days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: As needed acetaminophen (665 mg tablets as needed)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen
Number of subjects: 78

Group type: COMPARATOR
Intervention: As needed acetaminophen
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 16036010

Group type: EXPERIMENTAL
Intervention: Telecardiology
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 11870512

Group type: EXPERIMENTAL
Intervention: Multidisciplinary specialist genetics service
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Surgical consultation with specialist genetic risk assessment
Number of subjects: 735

Group type: COMPARATOR
Intervention: Surgical consultation without specialist genetic risk assessment
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Surgical consultation with or without specialist genetic risk assessment
Number of subjects: 735
Study: 10340981

Group type: EXPERIMENTAL
Intervention: Community optometrists
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Hospital eye service
Number of subjects: 405

Group type: COMPARATOR
Intervention: Research clinic reference standard
Number of subjects: 405
Study: 8722438

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg twice a day orally for 12 months)
Number of subjects: 16
Study: 1824732

Group type: EXPERIMENTAL
Intervention: Zoladex (3.6 mg of goserelin acetate)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Zoladex and Orchiectomy
Number of subjects: 164
Study: 6414571

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (ASA/DPM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 31836306

Group type: EXPERIMENTAL
Intervention: Point‐of‐Care systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Centralized laboratory
Number of subjects: 0
Study: 29190378

Group type: COMPARATOR
Intervention: English-text-and-pictograms
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Bilingual-text
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Bilingual-text-and-pictograms
Number of subjects: 1414
Study: 28658250

Group type: EXPERIMENTAL
Intervention: Public
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chefs and catering students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chefs in fine‐dining establishments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chefs in award-winning restaurants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Price of a meal and Food Hygiene Rating Score
Number of subjects: 0
Study: 26907864

Group type: COMPARATOR
Intervention: Recalling a prior DMV experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased levels of negative emotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recalling a frustrating DMV experience
Number of subjects: 0
Study: 25127244

Group type: EXPERIMENTAL
Intervention: PHiD-CV10 three plus one and two plus one schedules combined
Number of subjects: 47366
Study: 22237003

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 100 days (900 mg once daily)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 200 days (900 mg once daily)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 100 days
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 200 days
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Patients meeting resistance analysis criteria (RAC) during prophylaxis
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Patients not meeting RAC post-prophylaxis
Number of subjects: 318
Study: 19931952

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (2007 southern hemisphere influenza vaccine); coverage among ACF residents ranged from 59% to 100%.
Number of subjects: 0
Study: 17462091

Group type: EXPERIMENTAL
Intervention: Usual Care Plus Musculoskeletal Physiotherapy Treatment (UCMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC) administered by the General Practitioner (GP)
Number of subjects: 0
Study: 16302629

Group type: EXPERIMENTAL
Intervention: Transaxillary first rib resection (TFRR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Supraclavicular neuroplasty of brachial plexus (SNBP)
Number of subjects: 55
Study: 12042192

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 101
Study: 9733427

Group type: EXPERIMENTAL
Intervention: Distraction treatment (20 sessions)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Focusing treatment (20 sessions)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Combined groups (Distraction and Focusing)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Focusers
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Distracters
Number of subjects: 19
Study: 8555030

Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride 50 mg once daily for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1723447

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both HCTZ and nitrendipine
Number of subjects: 10
Study: 6781321

Group type: EXPERIMENTAL
Intervention: Oral diltiazem 90 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin 0.3 mg
Number of subjects: 9
Study: 30883589

Group type: EXPERIMENTAL
Intervention: Strategy 1: Direct contact attempts by up to 12 systematically timed phone calls
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Strategy 2: Personalized pre-notification letter to arrange for scheduled phone call interviews
Number of subjects: 370

Group type: COMPARATOR
Intervention: Validation population using Strategy 1
Number of subjects: 370
Study: 28029390

Group type: EXPERIMENTAL
Intervention: Olumacostat glasaretil (OG) 7.5% gel
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 108
Study: 25017924

Group type: EXPERIMENTAL
Intervention: Oral low-dose hormone therapy (estradiol 1 mg + drospirenone 2 mg/day) for 3 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-oral hormone therapy (1.5 mg/day percutaneous 17β-estradiol gel or equivalent for nasal route for 3 months followed by 200 mg/day micronized progesterone by the vaginal route for 14 days during each menstrual period)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-dose oral hormone therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-oral hormone therapy
Number of subjects: 44
Study: 23830706

Group type: EXPERIMENTAL
Intervention: Kinesiotaping group 1 (KT1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Kinesiotaping group 2 (KT2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham kinesiotaping (KT3)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Comparison of KT1 and KT2
Number of subjects: 49
Study: 21484002

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation program with education and practical training along with home visits by a community health nurse
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine cardiac rehabilitation program in the rehabilitation center (Control)
Number of subjects: 80
Study: 19330665

Group type: EXPERIMENTAL
Intervention: Junior doctor-led prescribing tutorial
Number of subjects: 271
Study: 17578315

Group type: EXPERIMENTAL
Intervention: Shengxueling (SXL), 60 mg twice a day for two weeks, then doubled if no marked rise in platelet count, administered for another two weeks.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ampeptide elemente, 0.4 g three times a day for two weeks, then adjusted to 0.2 g each time for a total of 1.8 g a day for two more weeks.
Number of subjects: 69
Study: 15272511

Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel (control)
Number of subjects: 20
Study: 11603386

Group type: EXPERIMENTAL
Intervention: Serum levels of SP-D in SSc patients with Barnett type III
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Serum levels of SP-D in SSD patients
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Serum levels of SP-D in SSc patients with anti-topoisomerase I antibodies
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Correlation analysis of SP-D levels with pulmonary fibrosis severity
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Correlation analysis of SP-D levels with vital capacity and %DLco
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Correlation analysis of SP-D levels with forced expiratory volume (FEV1.0%)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pre- and post-therapy with photopheresis
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Correlation between serum levels of SP-D and KL-6
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Plasma levels of SP-D in the group of collagen diseases
Number of subjects: 219

Group type: COMPARATOR
Intervention: Comparison of SP-D levels between SSc patients and other collagen diseases and dermatitis
Number of subjects: 219
Study: 9640884

Group type: EXPERIMENTAL
Intervention: Imiquimod cream (1%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8081786

Group type: EXPERIMENTAL
Intervention: Intravenous OKT3 for seven days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous CsA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients experiencing rejection episodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients not receiving OKT3
Number of subjects: 0
Study: 2510273

Group type: EXPERIMENTAL
Intervention: Anti-ulcer prostaglandins (misoprostol, enprostil, rioprostil)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: H2-blockers
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Anti-ulcer prostaglandins
Number of subjects: 5000
Study: 32930

Group type: EXPERIMENTAL
Intervention: Formula with higher osmolar load (539 mosm/1) and containing protein hydrolysate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formulas with varying osmolarity and MCT content
Number of subjects: 27
Study: 31461720

Group type: EXPERIMENTAL
Intervention: Cricothyroid method
Number of subjects: 500
Study: 27161196

Group type: EXPERIMENTAL
Intervention: Videoinsight psychological enhancing method (art video shown before rehabilitation sessions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no video support)
Number of subjects: 110
Study: 25564143

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily for 4 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23299606

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Continuous morphine
Number of subjects: 71
Study: 21856767

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: SRE gene signature
Number of subjects: 261
Study: 19726374

Group type: EXPERIMENTAL
Intervention: Prednisone and Hp eradication (group A, 51 cases)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Prednisone without Hp eradication (group B, 42 cases)
Number of subjects: 93
Study: 17488771

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60 mg acute loading dose prior to PCI
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (no TMZ)
Number of subjects: 266
Study: 15487709

Group type: EXPERIMENTAL
Intervention: Native sodium hyaluronate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cross‐linked hylan G‐F 20
Number of subjects: 40
Study: 11742047

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg once daily for 12 months)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Naltrexone (3 months) followed by placebo (9 months)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo (12 months)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: All groups (at 52 weeks)
Number of subjects: 627
Study: 9631345

Group type: EXPERIMENTAL
Intervention: Expectancy ratings during therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of Object Relations (QOR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 0
Study: 8164015

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 3495775

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus toxoids-acellular pertussis vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diphtheria-tetanus toxoids-whole cell pertussis vaccine
Number of subjects: 120
Study: 29659967

Group type: EXPERIMENTAL
Intervention: Rice with large green lentils
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rice with small green lentils
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rice with split red lentils
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Potato with large green lentils
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Potato with small green lentils
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Potato with split red lentils
Number of subjects: 48

Group type: COMPARATOR
Intervention: Potato alone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rice alone
Number of subjects: 48
Study: 28501812

Group type: EXPERIMENTAL
Intervention: Culturally adapted physiotherapy assessment and treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Evidence informed usual physiotherapy care
Number of subjects: 48
Study: 25661476

Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-fat dairy diet
Number of subjects: 15
Study: 24142616

Group type: EXPERIMENTAL
Intervention: Dermoxen® Lenitiva cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: methylprednisolone aceponate 0.1% based cream
Number of subjects: 80
Study: 21945310

Group type: EXPERIMENTAL
Intervention: Sequential docetaxel followed by carboplatin (sDC)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Combination docetaxel and carboplatin (cDC)
Number of subjects: 148
Study: 19099676

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg/d
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral montelukast 5 mg, once at bedtime for 6 months
Number of subjects: 84
Study: 16971666

Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) expression
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 967
Study: 14570509

Group type: EXPERIMENTAL
Intervention: Demands of divided attention during delay periods with interruptions (Experiment 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Strategic rehearsal and implementation intention strategies (Experiments 2 and 3)
Number of subjects: 3
Study: 11103758

Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alpha2b
Number of subjects: 58

Group type: COMPARATOR
Intervention: Interferon‐alpha2b (active control)
Number of subjects: 58
Study: 8932888

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (structured activities and informal support)
Number of subjects: 40
Study: 1416128

Group type: EXPERIMENTAL
Intervention: nalbuphine 5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: naloxone 0.2 mg
Number of subjects: 40
Study: 3927165

Group type: EXPERIMENTAL
Intervention: No cost sharing (0% coinsurance)
Number of subjects: 3973

Group type: EXPERIMENTAL
Intervention: Lower third of income distribution
Number of subjects: 3973

Group type: COMPARATOR
Intervention: Cost sharing (25%, 50%, 95% coinsurance)
Number of subjects: 3973
Study: 31576513

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg
Number of subjects: 192

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Control)
Number of subjects: 192
Study: 28401771

Group type: EXPERIMENTAL
Intervention: Preoperative breast magnetic resonance imaging
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no preoperative breast magnetic resonance imaging)
Number of subjects: 100
Study: 27903341

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (D group) - received a loading dose of 0.3 μg/kg followed by a continuous infusion of 0.2-0.4 μg·kg-1·min-1 of dexmedetomidine and sufentanil (0.1 μg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol group (P group) - received sufentanil 0.1 μg/kg and propofol 1.5 mg/kg followed by a continuous infusion of 3-6 mg·kg-1·h-1 of propofol
Number of subjects: 60
Study: 24990091

Group type: EXPERIMENTAL
Intervention: L100/H12.5
Number of subjects: 0

Group type: COMPARATOR
Intervention: L100
Number of subjects: 0

Group type: COMPARATOR
Intervention: L50/H12.5
Number of subjects: 0
Study: 22048884

Group type: EXPERIMENTAL
Intervention: GSK372475 (1-2 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (venlafaxine XR 150-225 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (paroxetine 20-30 mg/d)
Number of subjects: 0
Study: 20532709

Group type: EXPERIMENTAL
Intervention: Optimized three-layer tablet of venlafaxine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed extended release capsule of venlafaxine hydrochloride
Number of subjects: 0
Study: 18622777

Group type: EXPERIMENTAL
Intervention: Writing about the first psychotic episode
Number of subjects: 37

Group type: COMPARATOR
Intervention: Writing about time management
Number of subjects: 37
Study: 17166333

Group type: EXPERIMENTAL
Intervention: epoetin delta 150 IU/kg and 300 IU/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: epoetin delta 15 IU/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: epoetin alfa 50 IU/kg
Number of subjects: 0
Study: 12716662

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (S, P, M)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unsaturated fatty acids (O, T, L)
Number of subjects: 16
Study: 10981217

Group type: EXPERIMENTAL
Intervention: Various treatment modalities for acute dislocation of the patella; specific treatments not detailed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various treatment modalities for recurrent dislocation of the patella; specific treatments not detailed
Number of subjects: 0
Study: 8766874

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) intravenous bolus of 50 IU/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: UFH infusion
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single LMWH subcutaneous injection of 3,075 IU
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LMWH regimens
Number of subjects: 72
Study: 1435590

Group type: EXPERIMENTAL
Intervention: Praziquantel therapy at a daily dose of 25 mg/kg for 2 days
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Chloxilin, medamin, or praziquantel (other therapeutic schemes)
Number of subjects: 1599
Study: 6376718

Group type: EXPERIMENTAL
Intervention: Four-drug combination chemotherapy program with CCNU
Number of subjects: 417

Group type: COMPARATOR
Intervention: Four-drug combination chemotherapy program with mechlorethamine
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: CCNU-containing programs
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Age less than 40
Number of subjects: 417
Study: 30202873

Group type: EXPERIMENTAL
Intervention: Split-virion inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28323291

Group type: EXPERIMENTAL
Intervention: Utrogestan
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Crinone 8%
Number of subjects: 111
Study: 25765835

Group type: EXPERIMENTAL
Intervention: Silymarin supplementation (140 mg, thrice daily for 45 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Silymarin supplementation
Number of subjects: 40
Study: 25159238

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 56
Study: 22676069

Group type: EXPERIMENTAL
Intervention: Intervention group (tailored action plan for high risk premises)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 19594090

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 157

Group type: COMPARATOR
Intervention: gelatin
Number of subjects: 157
Study: 17894651

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (low exposure category)
Number of subjects: 6301

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (intermediate exposure category)
Number of subjects: 6301

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (high exposure category)
Number of subjects: 6301

Group type: COMPARATOR
Intervention: Control group (baseline exposure in North America)
Number of subjects: 6301
Study: 15286137

Group type: EXPERIMENTAL
Intervention: Weighted analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unweighted analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-effects model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random-effects model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type II analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type III analysis
Number of subjects: 0
Study: 11570639

Group type: EXPERIMENTAL
Intervention: Patients with psoriasis vulgaris (PV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 9631665

Group type: EXPERIMENTAL
Intervention: Screening SIRS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Original SIRS
Number of subjects: 75